This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Rizzieri, D. A. Articles by Giles, F. J. PubMed PubMed Citation Articles by Rizzieri, D. A. Articles by Giles, F. J.

A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies

Authors' Affiliations: ¹ Duke University Medical Center, Durham, North Carolina; ² Weill Medical College of Cornell University, New York, New York; ³ Washington University Medical Center, St. Louis, Missouri; ⁴ Gabrail Cancer Center, Canton, Ohio; ⁵ University of Chicago Department of Medicine and Cancer Research Center, Chicago, Illinois; ⁶ Cancer Institute of New Jersey, New Brunswick, New Jersey; ⁷ ARIAD Pharmaceuticals, Inc., Cambridge, Massachusetts; ⁸ Quest Diagnostics, Nichols Institute, San Juan Capistrano, California; and ⁹ University of Texas Health Science Center at San Antonio, San Antonio, Texas

Requests for reprints: David A. Rizzieri, Box 3961, DUMC, 2400 Pratt Street, Duke North Pavilion, Durham, NC 27710. Phone: 919-668-1040; Fax: 919-668-1091; E-mail: rizzi003{at}mc.duke.edu.

Purpose: Deforolimus (AP23573), a novel non-prodrug rapamycin analogue, inhibits the mammalian target of rapamycin, a downstream effector of the phosphatidylinositol 3-kinase/Akt and nutrient-sensing pathways. A phase 2 trial was conducted to determine the efficacy and safety of single-agent deforolimus in patients with relapsed or refractory hematologic malignancies.

Experimental Design: Eligible patients were assigned to one of five disease-specific, parallel cohorts and given 12.5 mg deforolimus as a 30-minute infusion once daily for 5 days every 2 weeks. A Simon two-stage design was used for each cohort. Safety, pharmacokinetics, pharmacodynamics, and antitumor response were assessed.

Results: Fifty-five patients received deforolimus as follows: cohort 1 23 acute myelogenous leukemia, two myelodysplastic syndrome and one chronic myelogenous leukemia in nonlymphoid blast phase; cohort 2, one acute lymphocytic leukemia; cohort 3, nine agnogenic myeloid metaplasia; cohort 4, eight chronic lymphocytic leukemia; cohort 5, nine mantle cell lymphoma and two T-cell leukemia/lymphoma. Most patients were heavily pretreated. Of the 52 evaluable patients, partial responses were noted in five (10%), two of seven agnogenic myeloid metaplasia and three of nine mantle cell lymphoma. Hematologic improvement/stable disease was observed in 21 (40%). Common treatment-related adverse events, which were generally mild and reversible, were mouth sores, fatigue, nausea, and thrombocytopenia. Decreased levels of phosphorylated 4E-BP1 in 9 of 11 acute myelogenous leukemia/myelodysplastic syndrome patients after therapy showed mammalian target of rapamycin inhibition by deforolimus.

Conclusions: Deforolimus was well-tolerated in patients with heavily pretreated hematologic malignancies, and antitumor activity was observed. Further investigation of deforolimus alone and in combination with other therapeutic agents is warranted in patients with selected hematologic malignancies.